Pharvaris plans filings for HAE drug after pivotal trial win
Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Sandoz says it is entering "golden decade" in biosimilars
Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
It turns out COPD may be a laughing matter after all
Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.
Novartis falls sharply on another major R&D setback
Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.
Pharma body sees 'green shoots' in UK investment
The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications
Better Antifibrotic Decisions Through Cross-Organ Insights
The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development
10th Dermatology Drug Development Summit
The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities